Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19

Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19

The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish...

Full description

Bibliographic Details
Main Authors: Madhan Jeyaraman, Sathish Muthu, Asawari Bapat, Rashmi Jain, E.S. Sushmitha, Arun Gulati, Talagavadi Channaiah Anudeep, Shirodkar Jaswandi Dilip, Niraj Kumar Jha, Dhruv Kumar, Kavindra Kumar Kesari, Shreesh Ojha, Sunny Dholpuria, Gaurav Gupta, Harish Dureja, Dinesh Kumar Chellappan, Sachin Kumar Singh, Kamal Dua, Saurabh Kumar Jha
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Heliyon
Subjects:
SARS-CoV-2
COVID-19
Natural killer cells
Cytokines
Pulmonary inflammation
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844021017382

Internet

http://www.sciencedirect.com/science/article/pii/S2405844021017382

Similar Items